新城雄士（https://researchmap.jp/arashirotakeshi）
ミネソタ大学生物学部 遺伝学専攻 卒業（BS）
東京医科歯科大学（現・東京科学大学） 医学部医学科 編入・卒業（MD）
ロンドン大学衛生熱帯医学大学院・長崎大学 卒業（PhD in Global Health）
千葉県の総合病院 国保 旭中央病院で初期研修終了後、東京医科歯科大学医学部付属病院 感染制御部で院内感染対策に従事。国立感染症研究所 感染症疫学センター・感染病理部の研究員として国のサーベイランスに従事し、新型コロナワクチンの有効性評価など感染症疫学研究を多数主導・関与。その後、民間のワクチン部門メディカルマネジャー・エビデンスジェネレーションリードを経て、現職として千葉大学 医学研究院 感染病態学 特任准教授および国立危機管理研究機構 国立感染症研究所 感染病理部 統合病理室 室長（インフルエンザ研究センターおよび感染症疫学センター併任）。慶應義塾大学 感染症学講座 特任講師、感染症内科クリニック非常勤勤務医としても活動。
【主な活動内容】
私自身の専門は、主に感染症分野における疫学や公衆衛生ですが、ラボ全体のコンセプトとして「異分野融合型の感染症研究」とある通り、これまでの経験を生かして、基礎医学も含めて、縦割りではない領域横断的な活動で微力ながら感染症対策への貢献ができればと考えております。
・公衆衛生・社会的対策（Public Health and Social Measures (PHSM) ）の有効性評価やこのモニタリング
・ワクチン等の臨床的・疫学的有効性評価、免疫応答評価
・その他、流行感染症対策やパンデミック対策に資する臨床疫学研究のデザイン・実装や公衆衛生活動
活動内容にご興味があればお問い合わせください：arashirot@chiba-u.jp
【免許・資格等】
日本医師会認定産業医（2025年）
医師免許（2018年）
【受賞歴等】
長崎大学 博士課程 学長賞（2024年）
Young Investigator Award, 11th Asian Congress of Pediatric Infectious Diseases (ACPID) in Hong Kong（2024年）
【所属学会】
日本感染症学会会員、日本ワクチン学会会員、日本公衆衛生学会会員、日本疫学会会員
【主要な研究業績】
1. Arashiro T*, Berba RP, Calayo JP, Solante R, Suzuki S, Shin J, Suzuki M, Hibberd M, Ariyoshi K, Smith C. Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics. Western Pacific Surveillance and Response, 16(2):1-8, 2025 (*corresponding author)
2. Arashiro T*, Berba RP, Calayo JP, Kris M, Garcia RM, Suzuki S, Dungog C, Rivera J, Malijan GM, Agrupis KA, Salazar MJ, Salazar MA, Shin J, Hibberd M, Ariyoshi K, Smith C. Sociobehavioural factors associated with SARS-CoV-2 infection and COVID-19 vaccine effectiveness against medically attended, symptomatic SARS-CoV-2 infection in the Philippines: a prospective case-control study (FASCINATE-P study). Western Pacific Surveillance and Response, 16(1):1-12, 2025 (*corresponding author)
3. Arashiro T*, Solante R, Sayo AR, Garcia RM, Kris M, Suzuki S, Malijan GM, Salazar MJ, Salazar MA, Ortal-Cruz A, Go GD, Miranda E, Carandang-Cuvin M, Calayo JP, Shin J, Hibberd M, Ariyoshi K, Smith C. Factors associated with COVID-19 in-hospital death and COVID-19 vaccine effectiveness against COVID-19 hospitalization in the Philippines during pre-omicron and omicron period: A case-control study (MOTIVATE-P study). Epidemiology and Infection, 153:e18, 2024 (*corresponding author)
4. Arashiro T*, Kramer R, Jin J, Kano M, Wang F, Miyairi I. Inpatient Burden of Respiratory Syncytial Virus Infection and Influenza in Children Younger Than 5 Years in Japan, 2011-2022: A Database Study. Influenza and Other Respiratory Viruses, 18(11):e70045, 2024 (*corresponding author)
5. Arashiro T, Tajima Y, Ban Y, Loiacono MM, Ideguchi M, de Courville C. The Burden of Seasonal Influenza and Its Potential Complications Among Older Japanese Adults: A Real-World Database Study. Influenza and Other Respiratory Viruses, 18(11):e70032, 2024
6. Arashiro T, Arima Y, Takahashi T, Taniguchi K, Horiguchi H, Suzuki M. Usefulness of a Pluralistic Approach in Sentinel Surveillance: Seasonal Influenza Activity Based on Case Counts per Sentinel Site in the National Epidemiological Surveillance of Infectious Diseases Program and Test Counts, Case Counts, and Test Positivity from the National Hospital Organization. Japanese Journal of Infectious Diseases, 77(5):296-300, 2024
7. Arashiro T*, Miwa M, Nakagawa H, Takamatsu J, Oba K, Fujimi S, Kikuchi H, Iwasawa T, Kanbe F, Oyama K, Kanai M, Ogata Y, Asakura T, Asami T, Mizuno K, Sugita M, Jinta T, Nishida Y, Kato H, Atagi K, Higaki T, Nakano Y, Tsutsumi T, Doi K, Okugawa S, Ueda A, Nakamura A, Yoshida T, Shimada-Sammori K, Shimizu K, Fujita Y, Okochi Y, Tochitani K, Nakanishi A, Rinka H, Taniyama D, Yamaguchi A, Uchikura T, Matsunaga M, Aono H, Hamaguchi M, Motoda K, Nakayama S, Yamamoto K, Oka H, Tanaka K, Inoue T, Kobayashi M, Fujitani S, Tsukahara M, Takeda S, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Fujino Y, Arima Y, Takeda S, Hashimoto S, Suzuki M. COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study). Vaccine, 42(3):677-688, 2024 (*corresponding author)
8. Arashiro T*, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Oba K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Nagura Y, Yanai H, Ueda A, Numata A, Kato H, Oka H, Nishida Y, Ishii K, Ooki T, Nidaira Y, Asami T, Jinta T, Nakamura A, Taniyama D, Yamamoto K, Tanaka K, Ueshima K, Fuwa T, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan. Vaccine, 41(47):6969-6979, 2023 (*corresponding author)
9. Arashiro T*, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Ueda A, Kato H, Oka H, Nishida Y, Nidaira Y, Asami T, Jinta T, Nakamura A, Oba K, Taniyama D, Yamamoto K, Tanaka K, Ueshima K, Fuwa T, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan. Open Forum Infectious Diseases, 10(6):ofad240, 2023 (*corresponding author) (Editor’s choice)
10. Arashiro T, Arai S, Kinoshita R, Otani K, Miyamoto S, Yoneoka D, Kamigaki T, Takahashi H, Hibino H, Okuyama M, Hayashi A, Kikuchi F, Morino S, Takanashi S, Wakita T, Tanaka-Taya K, Suzuki T, Suzuki M. National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan. Influenza and Other Respiratory Viruses, 17(2):e13094, 2023 (top 10 most-cited papers in 2023)
11. Arashiro T*, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Oba K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Nagura Y, Yanai H, Ueda A, Numata A, Kato H, Oka H, Nishida Y, Ooki T, Nidaira Y, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies. Eurosurveillance, 28(4):2300034, 2023
12. Miyamoto S*, Arashiro T*, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T. Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization. iScience, 26(2):105969, 2023 (*co-first)
13. Hirata Y, Iida S, Arashiro T, Nagasawa S, Saitoh H, Abe H, Ikemura M, Makino Y, Sawa R, Iwase H, Ushiku T, Suzuki T, Akitomi S. Impact of the COVID-19 pandemic on pathological autopsy practices in Japan. Pathology International, 73(3):120-126, 2023
14. Arashiro T*, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, Arioka H, Yanai H, Kuramochi J, Ihara G, Chubachi K, Yanagisawa N, Nagura Y, Kato Y, Ueda A, Numata A, Kato H, Ishii K, Ooki T, Oka H, Nishida Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (FASCINATE study). Clinical Infectious Diseases,76(3):e108-e115, 2023 (*corresponding author)
15. Arashiro T*, Arima Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Social and Behavioral Factors Associated with Lack of Intent to Receive COVID-19 Vaccine, Japan. Emerging Infectious Diseases, 28(9):1909-1910, 2022 (*corresponding author)
16. Arashiro T*, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, Arioka H, Yanai H, Yanagisawa N, Nagura Y, Kato Y, Kato H, Ueda A, Ishii K, Ooki T, Oka H, Nishida Y, Stucky A, Miyahara R, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Behavioral factors associated with SARS-CoV-2 infection in Japan. Influenza and Other Respiratory Viruses, 16(5):952-961, 2022 (*corresponding author)
17. Miyamoto S*, Arashiro T*, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Med. 3(4):249-261.e4, 2022 (*co-first)
18. Arima Y, Kanou K, Arashiro T, K Ko Y, Otani K, Tsuchihashi Y, Takahashi T, Miyahara R, Sunagawa T, Suzuki M. Epidemiology of Coronavirus Disease 2019 in Japan: Descriptive Findings and Lessons Learned through Surveillance during the First Three Waves. JMA Journal, 4(3):198-206, 2021
19. Iida S, Arashiro T, Suzuki T. Insights into Pathology and Pathogenesis of Coronavirus Disease 2019 from a Histopathological and Immunological Perspective. JMA Journal, 4(3):179-186, 2021
20. Arashiro T*, Nakamura S, Asami T, Mikuni H, Fujiwara E, Sakamoto S, Miura R, Shionoya Y, Honda R, Furukawa K, Nakamura A, Saito H. SARS-CoV-2 and Legionella co-infection in a person returning from a Nile cruise. Journal of Travel Medicine, 27(3):taaa053, 2020 (*corresponding author)
21. Arashiro T*, Furukawa K, Nakamura A. COVID-19 in 2 Persons with Mild Upper Respiratory Tract Symptoms on a Cruise Ship, Japan. Emerging Infectious Diseases, 26(6):1345-1348, 2020 (*corresponding author)
22. Suzuki T, Sato Y, Sano K, Arashiro T, Katano H, Nakajima N, Shimojima M, Kataoka M, Takahashi K, Wada Y, Morikawa S, Fukushi S, Yoshikawa T, Saijo M, Hasegawa H. Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections. Journal of Clinical Investigation, 130(2):799-812, 2020
23. Ly S, Arashiro T, Ieng V, Tsuyuoka R, Parry A, Horwood P, Heng S, Hamid S, Vandemaele K, Chin S, Sar B, Arima Y. Establishing seasonal and alert influenza thresholds in Cambodia using the WHO method: implications for effective utilization of influenza surveillance in the tropics and subtropics. Western Pacific Surveillance and Response, 8(1):22-32, 2017
24. Fukusumi M, Arashiro T, Arima Y, Matsui T, Shimada T, Kinoshita H, Arashiro A, Takasaki T, Sunagawa T, Oishi K. Dengue Sentinel Traveler Surveillance: Monthly and Yearly Notification Trends among Japanese Travelers, 2006-2014. PLOS Neglected Tropical Diseases, 10(8):e0004924, 2016
25. Levings DC, Arashiro T, Nakato H. Heparan sulfate regulates the number and centrosome positioning of Drosophila male germline stem cells. Molecular Biology of the Cell, 27(6):888-96, 2016